- Home
- GBIO vs ABAT Comparison
GBIO vs ABAT Comparison
Compare GBIO & ABAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- ABAT
- Stock Information
- Founded
- GBIO 2016
- ABAT 2011
- Country
- GBIO United States
- ABAT United States
- Employees
- GBIO N/A
- ABAT N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- ABAT Metal Mining
- Sector
- GBIO Health Care
- ABAT Basic Materials
- Exchange
- GBIO Nasdaq
- ABAT Nasdaq
- Market Cap
- GBIO 64.8M
- ABAT 71.7M
- IPO Year
- GBIO 2020
- ABAT N/A
- Fundamental
- Price
- GBIO $0.78
- ABAT $1.52
- Analyst Decision
- GBIO Strong Buy
- ABAT
- Analyst Count
- GBIO 2
- ABAT 0
- Target Price
- GBIO $6.50
- ABAT N/A
- AVG Volume (30 Days)
- GBIO 649.2K
- ABAT 4.0M
- Earning Date
- GBIO 03-05-2025
- ABAT 02-16-2025
- Dividend Yield
- GBIO N/A
- ABAT N/A
- EPS Growth
- GBIO N/A
- ABAT N/A
- EPS
- GBIO N/A
- ABAT N/A
- Revenue
- GBIO $18,582,000.00
- ABAT $545,460.00
- Revenue This Year
- GBIO $212.74
- ABAT $31,748.62
- Revenue Next Year
- GBIO N/A
- ABAT N/A
- P/E Ratio
- GBIO N/A
- ABAT N/A
- Revenue Growth
- GBIO 514.08
- ABAT N/A
- 52 Week Low
- GBIO $0.72
- ABAT $0.73
- 52 Week High
- GBIO $4.65
- ABAT $4.11
- Technical
- Relative Strength Index (RSI)
- GBIO 29.26
- ABAT 46.27
- Support Level
- GBIO $0.72
- ABAT $1.32
- Resistance Level
- GBIO $1.00
- ABAT $1.65
- Average True Range (ATR)
- GBIO 0.07
- ABAT 0.19
- MACD
- GBIO -0.00
- ABAT -0.05
- Stochastic Oscillator
- GBIO 18.68
- ABAT 29.41
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.